In prostate cancer, the loss-of-function mutation of SPOP (an E3 ubiquitin ligase of Brd4) has been shown to confer resistance to BET inhibitors by impairing ubiquitination-mediated Brd4 degradation [157,158]. Here, BRD4 is linked to Familial prostate cancer.